Ajjai Shivaram Alva, MBBS

home / authors / ajjai-shivaram-alva-mbbs

Articles

Dr. Alva on the Shift Toward Combination Therapy in mRCC

Dr. Alva on the Shift Toward Combination Therapy in mRCC

Ajjai Shivaram Alva, MBBS
February 15th 2020

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Read More

Dr. Alva on Results of the CABOSUN Trial in RCC

Dr. Alva on Results of the CABOSUN Trial in RCC

Ajjai Shivaram Alva, MBBS
February 4th 2020

Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.

Read More

Dr. Alva on TKI Monotherapy and Combinations for RCC

Dr. Alva on TKI Monotherapy and Combinations for RCC

Ajjai Shivaram Alva, MBBS
January 22nd 2020

Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.

Read More

Dr. Alva on the Toxicity Profiles of TKIs in RCC

Dr. Alva on the Toxicity Profiles of TKIs in RCC

Ajjai Shivaram Alva, MBBS
January 6th 2020

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Read More

Latest Updated Articles

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Oleg Gluz, MD
Published: September 14th 2024 | Updated: September 25th 2024
Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer